<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19165">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02857400</url>
  </required_header>
  <id_info>
    <org_study_id>16GENE11</org_study_id>
    <nct_id>NCT02857400</nct_id>
  </id_info>
  <brief_title>Evaluation of an Organized Consultation &quot;Return Home&quot; of Patients With a Metastatic Cancer (CREDO)</brief_title>
  <acronym>CREDO</acronym>
  <official_title>Evaluation of an Organized Consultation &quot;Return Home&quot; of Patients With a Metastatic Cancer (CREDO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, open label, randomized and multicentric study evaluating the efficacy of an
      organized consultation &quot;return home&quot; compared to a current standard of care in patient
      hospitalized due to metastatic solid tumor cancer.

      Subject will be randomized (1:1) as described below :

      â€¢ Arm A (standard) : current standard of care ; connection documentation faxed to GP (
      General practitioner) on the day of patient's discharge Arm B (experimental) : CREDO
      standard of care, organized consultation &quot;return home&quot; between patient, GP DESC (diploma of
      complementary specialized study) and patient's referent GP
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of an organized consultation &quot;return home&quot; of patients with a metastatic cancer</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Evaluation of number of non planned consultation and hospitalization compared to current standard of care</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the 2 standard of care (current and CREDO) regarding subject' satisfaction</measure>
    <time_frame>up to 12 months</time_frame>
    <description>phone call , specific question</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the 2 standard of care (current and CREDO) regarding subject's quality of life</measure>
    <time_frame>up to 12 months</time_frame>
    <description>quality of life questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of the conformity of the standard of care regarding the place of care</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Comparison with the initial predefined place of standard of care</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">824</enrollment>
  <condition>METASTATIC CANCER</condition>
  <arm_group>
    <arm_group_label>Arm A (standard)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (experimental)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>current standard of care</intervention_name>
    <description>connection documentation faxed to GP (General practitioner) on the day of patient's discharge</description>
    <arm_group_label>Arm A (standard)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CREDO standard of care</intervention_name>
    <description>organized consultation &quot;return home&quot; between patient, GP DESC (diploma of complementary specialized study) and patient's referent GP</description>
    <arm_group_label>Arm B (experimental)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; 18 years old

          2. Subject hospitalized in an oncology dedicated center for administration of the first
             chemotherapy cycle.

          3. Subject with metastatic solid tumor whatever the organ

          4. subject planned to be discharged home after chemotherapy administration

          5. Affiliated to the French social security system.

          6. Subjects must provide written informed consent prior to any study-specific procedure
             or assessment

        Exclusion Criteria:

          1. Subject included in another trial with therapeutic purpose

          2. Subject or close circle if applicable unreachable by phone

          3. Pregnant or breastfeedings women

          4. Any serious and/or unstable pre-existing psychiatric,familial, geographic or social
             condition that could interfere with medical follow-up and compliance to study
             procedures

          5. Subject law protected
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Eve ROUGE BUGAT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Claudius Regaud</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie-Eve ROUGE BUGAT, MD</last_name>
    <phone>0033 05 31 15 51 22</phone>
    <email>rouge.marie-eve@iuct-oncopole.fr</email>
  </overall_contact>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 2, 2016</lastchanged_date>
  <firstreceived_date>July 28, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
